Recently，Antengene’s Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate), an elderly patient with advanced gastric cancer who has progressed on multiple lines of chemotherapy, immunotherapy and targeted therapy despite extensive metastases achieved a complete response (CR) following ATG-022 monotherapy. The patient’s tumor-free status was confirmed by PET/CT in May 2025.
At present, there are still many clinical trials of new anti-cancer technologies in China seeking patients. Consultation on new drugs and technologies, you can contact Beijing South Region Oncology Hospital International Department.
Phone Number：4008803716
WeChat ID: 17801183037
Email：myimmnet@163.com
ATG-022 is a CLDN18.2 ADC discovered and developed in-house by Antengene. At the ASCO GI 2025 conference earlier this year, Antengene presented updated clinical data for ATG-022. In patients with moderate-to-high CLDN18.2 expression (IHC 2+ ≥ 20%), the objective response rate (ORR) was 42.9%, and the disease control rate (DCR) was 95.2%. Among patients with low CLDN18.2 expression (IHC 2+ < 20%), the ORR was 30.0%, and the DCR was 50.0%. These data demonstrate that ATG-022 delivers clinically meaningful efficacy and favorable safety profile across a spectrum of CLDN18.2 expression levels, including high, low, and even ultra-low expression. Its broad-spectrum antitumor activity suggests that ATG-022 may offer therapeutic benefits to a wider patient population compared to other CLDN18.2-targeted therapies. Currently, the Phase II dose-expansion study of ATG-022 is ongoing in the mainland of China and Australia.
This achievement of a CR in this elderly gastric cancer patient is extremely encouraging, highlighting the therapeutic potential of ATG-022 as a novel ADC therapy. Importantly, this is not the only CR observed in the ongoing study. To date, three CR cases have been observed, including patients from both the mainland of China and Australia. Antengene looks forward to presenting updated data from the ATG-022 study at the upcoming ESMO Congress in October 2025.
At present, there are still many clinical trials of new anti-cancer technologies in China seeking patients. Consultation on new drugs and technologies, you can contact Beijing South Region Oncology Hospital International Department.
Phone Number：4008803716
WeChat ID: 17801183037
Email：myimmnet@163.com
Post time: Aug-21-2025